Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Accelerant Holdings reported a net income of $66.7 million for the nine months ended September 30, 2026, a significant recovery from a net loss of $1,346.1 million in the prior year period, which was heavily impacted by a $1.38 billion non-cash profits interest distribution expense. Total revenues grew to $908.8 million for the nine-month period, driven by increases in direct commission income and net earned premiums.
Starling Oncology, Inc. has prepared a formal investor presentation to be used in upcoming meetings with investors. The presentation, dated November 12, 2026, was furnished as an exhibit to the 8-K filing and includes a discussion of the company's strategy and financial trends.
Patriot National Bancorp reported a net income of $1.2 million for the third quarter of 2026, a significant improvement from a $2.7 million loss in the prior year period. Total assets grew to $1.5 billion as of September 30, 2026, driven by a substantial increase in loans receivable and deposits, though the company recorded a comprehensive loss of $17.7 million for the first nine months of 2026 due to unrealized losses on investment securities.
Hornbeck Offshore Services President & CEO Todd M. Hornbeck Buys $1.5M of Stock
Todd M. Hornbeck, President & CEO, bought 280,866 shares of Hornbeck Offshore Services, Inc. at $5.28 to $5.48 a share (average $5.34) in 2 transactions, worth $1.5M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 5,950,514 (+1.6%).
Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.
Term
Q3 2026
“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”
Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.
BTCS Inc. reported record Q3 2026 financial results, highlighted by a 67% sequential revenue increase to $4.1 million and record gross profit of $3.5 million. The company surpassed its full-year gross profit target of $6 million in just nine months, driven primarily by the expansion of its Imperium liquidity pool positions to approximately $41 million.
Term
Q3 2026
“The third quarter was a breakout quarter for BTCS and Imperium. BTCS delivered a record $3.5 million in gross profit at an 86% gross margin, surpassing our full-year gross profit target of $6 million with a full quarter remaining in 2026. That performance was driven by Imperium, where we grew our paired liquidity pool positions from approximately $8 million to approximately $41 million and expanded into a multi-chain strategy with the integration of Base. Looking to the fourth quarter, we intend to keep scaling Imperium, and we expect it to remain the leading driver of our business.”
Monopar Therapeutics reported third quarter 2026 financial results, including a net loss of $6.2 million and a cash position of $129.4 million. The company highlighted progress on its rolling NDA submission for ALXN1840 in Wilson disease, which it expects to complete within the next several weeks.
Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.
“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”
Prashant Kohli, Chief Executive Officer
“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”
Hancock Whitney Signs $3.2B M&A Deal with Trustmark Corporation
Hancock Whitney Corporation (HWC) has entered into a definitive agreement to acquire Trustmark Corporation (TRMK) in an all-stock transaction valued at approximately $3.2 billion. The merger will create a premier Gulf South regional bank with approximately $58 billion in assets and is expected to close in late Q1 2027.
Value
$3.2B
Counterparty
Trustmark Corporation
“By bringing together two high-performing banks with shared values, complementary capabilities, and a relentless focus on client success, we create an organization that is stronger as one. This combination enhances our platform, expands growth opportunities, strengthens the core deposit franchise, and broadens the capabilities we deliver to consumer and business clients.”
John M. Hairston, President and CEO of Hancock Whitney
“Given the strong cultural alignment and complementary business lines between our two organizations, we believe this transaction will generate substantial value and meaningful benefits for our customers, shareholders, associates, and communities.”
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on radiopharmaceuticals and copper-chelating therapies like ALXN1840. For the nine months ended September 30, 2026, the company reported 6,776,773 shares of common stock outstanding and continues to incur significant losses as it prepares a rolling NDA submission for ALXN1840.
Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.65M of Stock
Japan Post Holdings Co. Ltd. sold 13,000 shares of Aflac Inc at $125.77 to $127.55 a share (average $126.89) in 3 transactions, worth $1.65M in total on Nov 10, 2026. Shares held after the trade: 50,121,329 (-0.0%).
Artelo Biosciences reported a net loss of $7.15 million for the nine months ended September 30, 2026, compared to $8.71 million in the prior year period. The company strengthened its balance sheet through equity financing, ending the quarter with $4.44 million in cash and cash equivalents, up from $0.6 million at the start of the year.
Imunon, Inc. reported a net loss of $10.8 million for the nine months ended September 30, 2026, compared to $10.3 million in the prior year period. The company's cash position decreased to $4.0 million from $8.8 million at year-end 2025, while total liabilities increased significantly due to the issuance of new notes payable.
Datacentrex, Inc. has prepared and furnished a formal investor presentation deck (Exhibit 99.1) regarding its operations and performance. Management intends to use these materials for upcoming presentations to investors and analysts.
PVH Corp. launched a global enterprise-wide initiative to accelerate strategic priorities and improve productivity, which includes reducing its global workforce by approximately 4%. The company expects to achieve at least $100 million in pre-tax cost reductions in fiscal 2027, increasing to $150 million annually starting in fiscal 2028.
Lester R. Brafman resigned as Chief Executive Officer of Cohen & Co Inc. effective November 10, 2026, and will serve as a Senior Advisor through November 30, 2026. Daniel G. Cohen, the company's Executive Chairman and former CEO, has been appointed to succeed him as Chief Executive Officer. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Chenghe Acquisition III Co. reported a net income of $2,633,792 for the nine months ended September 30, 2026, primarily driven by $3,235,400 in interest earned on cash held in the Trust Account. As a shell company, it has not yet generated operating revenue and is currently focused on identifying a target for its initial Business Combination.
Accelerant Holdings reported third quarter 2026 financial results, highlighted by a 27% year-over-year growth in Exchange Written Premium to $1.33 billion. Despite a GAAP net loss of $9.2 million, the company achieved adjusted net income of $38.2 million and reaffirmed its pending merger with Thoma Bravo, expected to close in the first half of 2027.
“The third quarter continued to show the strength of the Accelerant Risk Exchange, with Exchange Written Premium growing 27% year-over-year to $1.33 billion. We added 26 MGAs during the quarter, maintaining the upward momentum of our high-quality, specialty underwriting talent.”
Jeff Radke, Accelerant’s Chairman and Chief Executive Officer
“We delivered another quarter of disciplined growth, with operating revenue of $280.2 million and adjusted EBITDA of $71.3 million. Our fee-based businesses, which we define as consolidated results less the Underwriting segment, delivered $84.5 million of adjusted EBITDA, representing growth of 75% year over year.”
Linda S. Huber, Accelerant’s Chief Financial Officer
ProMIS Neurosciences Inc. has posted an updated corporate presentation to its website and filed it as an exhibit to its 8-K. The presentation provides a strategic overview of the company's development pipeline, including its PMN310 candidate for Alzheimer's disease and the PRECISE-AD Phase 1b clinical trial. The filing serves as a Regulation FD disclosure to provide investors with current information on the company's operations and clinical milestones.
Imunon, Inc. reported financial results for the third quarter ended September 30, 2026, and provided updates on its lead clinical candidate IMNN-001 for advanced ovarian cancer. The company highlighted its Phase 3 OVATION 3 study and a recent Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to support further development of IMNN-001.
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer. The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
Tonix Pharmaceuticals Holding CEO Seth Lederman Buys $20.3K of Stock
Seth Lederman, CEO, bought 5,000 shares of Tonix Pharmaceuticals Holding Corp. at $4.05 a share, worth $20.3K in total on Nov 11, 2026. Shares held after the trade: 16,005 (+45.4%).
SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.
Term
Q3 2026
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”
Phoenix Education Partners, Inc. declared a special cash dividend of $2.36 per share. The dividend is payable on December 4, 2026, to stockholders of record as of November 23, 2026.
CarParts.com announced several changes to its Board committees, including the appointment of Warren Phelps, III as Chair of the Nominating and Corporate Governance Committee. Tim Nauss was appointed to both the Audit and Nominating committees, while Nanxi Liu and Dr. Lisa Costa stepped down from their roles on the Nominating and Corporate Governance Committee.
CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, while maintaining its full-year 2026 revenue guidance. The company also highlighted its pending acquisition of Heron Therapeutics assets and a new $150 million term loan facility to support the transaction and operations.
Term
Q3 2026
“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing.”
Joseph Todisco, Chairman & Chief Executive Officer
Skye Bioscience received a unanimous jury verdict in its favor following a retrial in the U.S. District Court for the Central District of California. The lawsuit, filed by a former employee, alleged whistleblower protection violations and retaliation related to events occurring between 2018 and 2019. The verdict clears the company of all claims, though the plaintiff retains the right to file post-trial motions or appeals.
MBX Biosciences Chairman, President and CEO Steven L. Hoerter Sells $268K of Stock
Steven L. Hoerter, Chairman, President and CEO, sold 4,893 shares of MBX Biosciences, Inc. at $54.82 a share, worth $268K in total on Nov 10, 2026. Shares held after the trade: 78,045 (-5.9%).
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) and its merger target Electra Vehicles, Inc. (ELECTRA AI) announced a three-year partnership where Electra will serve as the Official Battery Intelligence Partner for Westbrook Racing at the E1 Miami GP. This update provides a strategic and marketing milestone for the companies as they work toward completing their previously announced business combination agreement dated April 21, 2026.